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Summary
Phospholipase C epsilon 1 (PLCε1) is a unique member of the phospho-
lipase family, in that it also functions as a guanine nucleotide exchange 
factor (GEF) for the small GTPase Rap1. It is this function as a Rap1 
GEF that gives PLCε1 an essential role in chemokine-mediated T cell 
adhesion. We have utilized a syngeneic tumor model, MC38 cells in C57BL/6 
mice, and observed that tumors grow larger and more quickly in the 
absence of PLCε1. Single-cell analysis revealed an increased CD4+/CD8+ 
ratio in the spleens, lymph nodes and tumors of PLCε1 knock-out tumor-
bearing mice. T cells isolated from PLCε1 knock-out mice were less ac-
tivated by multiple phenotypical parameters than those from wild-type 
mice. We additionally noted a decrease in expression of the chemokine 
receptors C-X-C chemokine receptor type 4 (CXCR4) and C-C motif 
chemokine receptor 4 (CCR4) on CD4+ T cells from the spleens, lymph 
nodes and tumors of PLCε1 knock-out mice compared to wild-type mice, 
and diminished migration of PLCε1-depleted CD3+ T cells towards stromal 
cell-derived factor (SDF)-1α. Based on these results, we conclude that PLCε1 
is a potential regulator of tumor-infiltrating lymphocytes, functioning, at 
least in part, at the level of T cell trafficking and recruitment.
Keywords: chemokines, MC38, murine cancer model, phospholipase C epsilon 
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Introduction
T cell trafficking is a process that is shared by fighting 
pathogens, autoimmune diseases and tumor rejection. The 
directed movement of T cells throughout the body is 
primarily achieved by specific expression patterns of 
chemokines and chemokine receptors. In the context of 
solid tumors, enhancing T cell infiltration is an important 
therapeutic strategy, given our understanding of its being 
a reliable predictor of patient outcome [1–4]. Research 
aimed at understanding the tumor microenvironment has 
gained more traction in recent years, especially as T cell 
checkpoint inhibitors have proved successful in extending 
survival of patients unresponsive to other therapies. These 
therapeutics, including anti-programmed cell death 1 (PD-
1) and anti-cytotoxic T lymphocyte antigen (CTLA)-4 
antibodies, enhance T cell activation in an effort to pro-
mote tumor cell identification and elimination [5]. However, 
without effective T cell recruitment these therapeutics 
cannot work [6]. The influx of immune cells into the 
tumor microenvironment can be exploited by the cancer 
cells and contribute to tumor associated inflammation, 
thereby promoting tumor growth, progression and metas-
tasis [7].
As chemokine and chemokine receptor expression is 
regulated to maintain specificity of cellular recruitment, 
these signaling molecules make ideal targets for the 
selective intervention into T cell infiltration [6,8,9]. Many 
chemokine receptor antagonists that have entered clinical 
trials have lacked clinical benefit [10–12], due probably 
to intracellular signaling redundancy among different 
chemokine pathways, although this redundancy is yet to 
be elucidated. Our previous work shows that the enzyme 
phospholipase C epsilon 1 (PLCε1) plays a requisite role 
in C-X-C chemokine receptor type 4 (CXCR4) signaling 
in T cells [13]. In a model of contact sensitivity, PLCε1 
knock-out mice demonstrated major defects in T cell 
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trafficking and migration. This protein has been impli-
cated in the pathogenesis of numerous diseases [14,15]. 
The role of PLCε1 in tumor progression has primarily 
been explored in the context of activation state in cancer 
cells and the contribution to tumor progression from 
this perspective. The data on PLCε1 in cancer develop-
ment and progression has been well reviewed [16]. In 
this study, we aim to identify the specific contribution 
of PLCε1 to T cell tumor infiltration and to the anti-
tumor immune response. We report that PLCε1 plays a 
necessary role in T cell trafficking and activation in 
tumor-bearing mice. This work contributes to our under-
standing of the chemokine signaling network in T cells.
Materials and methods
Mice and tumor cell lines
Male, 6–8-week-old C57BL/6 (B6) wild-type (WT) or PLCε1 
knock-out mice (KO) [13,17] were used in all studies. Animal 
studies were approved by the New York University institutional 
animal care and use committee. The WT mice that were used 
for the control experiments were also used for the KO mice 
back-crossing, assuring a homogeneous genetic background. 
Mice were housed in the same facility for 1  week before 
experiment to synchronize environments. The murine colon 
adenocarcinoma (MC38) colon carcinoma cells were a gift 
from Ben Neel of New York University. Prior to use, MC38 
cells were authenticated by simple sequence length polymor-
phism (SSLP). The MC38 cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) medium supplemented 
with heat-inactivated fetal bovine serum (FBS; 10%) and 
penicillin–streptomycin (P/S; 10  000 U/ml stock; 1%) and 
grown at 37°C with 5% CO2. Cells were passaged prior to 
storage and thawed and passaged twice prior to implantation 
for all described tumor experiments. All cell lines were deter-
mined to be free of mycoplasma (Lonza, Basel, Switzerland).
Tumor model
MC38 (1  ×  106) cells were implanted subcutaneously in 
the right hind flank of mice. Tumor growth was monitored 
using electronic calipers and calculated according to the 
formula: V  =  length  ×  width2  ×  0·52. To analyze T cells, 
spleens, right inguinal lymph nodes and tumors from both 
groups were harvested for analysis 14 days post-tumor 
implantation. For survival experiments, mice were eutha-
nized when tumor size reached 2000 mm3 or when tumors 
became ulcerated. Tumor weight was measured on the 
day of euthanasia.
Flow cytometry
Cells freshly isolated from murine spleen, right inguinal 
lymph node and tumor were stained, non-permeabilized, 
with fluorescently conjugated antibodies specific for CD3, 
CD4, CD8, PD-1, CD44, CD62L, CD25, CXCR3, CCR4, 
CCR7 and CXCR4 (all from BioLegend, San Diego, CA, 
USA) in fluorescence activated cell sorter (FACS) buffer 
[phosphate-buffered saline (PBS) without Ca+2/Mg+2 
(FBS) (2%)]. Subsequently, these cells were fixed and 
permeabilized (True-Nuclear Transcription Factor Buffer 
Set; BioLegend) to stain with a fluorescently conjugated 
antibody specific for forkhead box protein 3 (FoxP3) 
(BioLegend). Events were recorded using the LSRII (BD 
Biosciences, San Jose, CA, USA) with single stain com-
pensation controls and fluorescence minus 1 controls. 
Compensation was performed using FACSDiva (BD 
Biosciences) and data were analyzed using FlowJo soft-
ware (TreeStar Inc., Ashland, OR, USA). Events were 
first gated based on forward (FSC)- and side-scatter 
(SSC); CD3+ events were then gated and subsequently 
gated into CD4+ and CD8+ populations. CD4+ and CD8+ 
populations were analyzed for PD-1, CD44, CD62L, CD25, 
CXCR3, CCR4, CCR7 and CXCR4 expression. Jurkat T 
cells were stained with allophycocyanin (APC)-conjugated 
mouse IgG2a κ or anti-human CXCR4 antibody 
(BioLegend). Events were recorded using the LSRFortessa 
(BD Biosciences) and data were analyzed using FlowJo 
software. All flow cytometry analysis was performed in 
adherence with the ‘Guidelines for the use of flow cytom-
etry and cell sorting in immunological studies’ (Cossarizza 
et al. [18]).
In-vitro CD8+ cytotoxicity assay
Splenocytes were isolated from 6–8-week-old B6 wild-
type or PLCε1 knock-out murine spleens and red blood 
cells were removed by ACK lysis buffer (Lonza). Washed 
splenocytes were then cultured in complete RPMI-1640 
medium supplemented with β-mercaptoethanol (55 µM), 
mouse interleukin (IL)-2 (1000 IU/ml) and Staphylococcus 
aureus enterotoxin E (SEE; 1 µg/ml) for 72 h at a density 
of 2  ×  107 cells/well in a 96-well plate, 37°C with 5% 
CO2. Raji B cells (American Type Culture Collection, 
Manassas, VA, USA) were maintained in complete RPMI-
1640 media supplemented with heat-inactivated FBS 
(10%) and P/S (1%) at 37°C with 5% CO2. After 72  h, 
CD8+ T cells were isolated from the splenocytes by 
negative selection (StemCell Technologies, Vancouver, 
Canada) and put into co-culture with Raji cells in the 
presence of IL-2 and SEE at the indicated ratios for 
4  h, after which lactate dehydrogenase (LDH) activity 
in the supernatant was assayed (ThermoScientific, 
Fremont, CA, USA).
Chemotaxis assay
The chemotaxis of PLCε1-depleted T cells towards the 
chemokine stromal cell-derived factor (SDF)-1α/CXCL12 
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(R&D Systems, Minneapolis, MN, USA) was assessed using 
24-well Transwell cell culture inserts with 5-µm pores 
(Corning, New York, NY, USA). CD3+ T cells were isolated 
through negative selection enrichment kit (Miltenyi Biotech, 
San Diego, CA, USA).
PLCε1 depletion was achieved by introducing inhibi-
tory RNA (Dharmacon, Lafayette, CO, USA), as previously 
described [8]. Control cells were transfected with a 
scrambled, non-targeting siRNA (Dharmacon). At the 
start of the assay, T cells were stained with 1  µM car-
boxyfluorescein succinimidyl ester (CFSE; BioLegend) and 
added to the apical compartment of the Transwell insert 
(100 µl RPMI-1640 media containing 10% FBS, 1·5 × 105 
cells/insert). The basolateral compartment was filled with 
600  µl of RPMI-1640 containing 10% FBS and 75  ng/
ml SDF-1α/CXCL12. Chemotaxis was allowed for 3  h 
at 37°C with 5% CO2. The media and cells from the 
basolateral compartment were then collected, cells were 
pelleted and resuspended in 130  µl of FACS buffer to 
be transferred to a 96-well plate. Cells that moved into 
the basolateral compartment were quantified by flow 
cytometry using uniform volume acquisition on the 
LSRFortessa (BD Biosciences) and analysis was performed 
using FlowJo software. Cells were gated based on FSC 
versus SSC morphology of primary T cells then on car-
boxyfluorescein succinimidyl ester (CFSE) positivity. The 
number of CFSE+ T cells was used to determine the 
percentage chemotaxis by dividing the number of CFSE+ 
siScramble or siPLCε1 CD3+ T cells by the number of 
CFSE+ siScramble cells, therefore normalizing siScramble 
chemotaxis to 100%.
Statistics
Values are reported as means  ±  standard error of the 
mean (s.e.m.). Statistical analyses were performed using 
Student’s t-test in GraphPad Prism (version 7.0c).
Results
PLCε1 limits MC38 tumor growth and contributes to T 
cell subset distribution
Our previous work shows that the enzyme PLCε1 plays a 
requisite role in CXCR4 signaling in T cells [13]. Within 
the colorectal cancer samples included in The Cancer Genome 
Atlas (TCGA) (http://www.oncol nc.org/kapla n/?lower = 
33&upper = 33&cance r  =  READ&gene_id  =  51196 
&raw  =  plce1 &speci es = mRNA), high PLCε1 expression 
correlates with greater 5-year survival (Supporting informa-
tion, Fig. S1a). We implanted MC38 cells into C57BL/6 
wild-type (WT) or PLCε1 knock-out (KO) mice and observed 
that tumors grew larger in the KO mice (Fig. 1a and 
Supporting information, Fig. S1b). We next isolated cells 
from the tumors, right inguinal lymph nodes (LN) and 
spleens of mice 14  days after MC38 cell implantation or 
spleens of non-tumor-bearing mice and analyzed by flow 
cytometry. In the spleens of non-tumor-bearing mice, CD4+/
CD8+ ratios were equivalent between WT and KO mice 
(Fig. 1b). Following 14 days of tumor growth, the CD4+/
CD8+ ratio in the spleens decreased in WT mice, although 
not in KO mice (Fig. 1c). Similarly, the CD4+/CD8+ ratio 
was higher in the LN and tumors of KO mice compared 
to the same sites in WT mice (Fig. 1d,e). At all sites, the 
increase in CD4+ T cells could not be accounted for by 
regulatory T cells, as there was no difference observed in 
this subset (Supporting information, Fig. S2).
Activation of tumor-infiltrating T cells requires PLCε1
To assess the activation state of the CD4+ and the CD8+ 
cells, we determined surface expression of CD44, CD62L 
and PD-1. Overall, significantly fewer KO CD4+ T cells 
expressed CD44 and PD-1 in the spleens, LN and tumors 
(Fig. 2a and Supporting information, Fig. S3). Additionally, 
there was an increased presence of naive CD4+ T cells 
(naive; CD62L+CD44−) at all three sites (Fig. 2b). Fewer 
CD44+ CD8+ T cells were observed isolated from the 
spleens, LN and tumors of KO mice (Fig. 2c). The major-
ity of CD8+ T cells isolated from all sites in KO mice 
were naive, with a near absence of central memory (Tcm; 
CD62L+CD44+) and effector memory (Tem; 
CD62L−CD44+) populations (Fig. 2d), demonstrating over-
all lower activation in the absence of PLCε1. Unexpectedly, 
and unlike the CD4+-infiltrating T cells, many of the 
CD8+-infiltrating T cells were negative for PD-1 (Fig. 2d).
Infiltrating T cells express different chemokine 
receptors in the absence of PLCε1
This observation of lower T cell activation could be due 
to a role for PLCε1 in T cell receptor (TCR) signaling 
or to improper localization with other cells in the micro-
environment. Accordingly, we isolated CD8+ T cells and 
assessed non-specific cytotoxic activity. Nevertheless, PLCε1 
KO T cells could induce Raji cell cytotoxicity to the same 
extent as WT CD8+ T cells in the presence of superantigen 
SEE (Fig. 3a). This suggests that PLCε1 does not contribute 
to T cell effector function, and leaves open the possibility 
that cellular mislocalization to or within the tumor is 
responsible for the observed lack of activation.
When assessing the expression levels of various 
chemokine receptors on the surface of T cells isolated 
from the spleens, LN and tumors, we found that fewer 
KO CD4+ T cells isolated from the spleens and tumors 
expressed CCR4 (Fig. 3b). Within the LN, fewer CD4+ 
T cells expressed CCR4 in KO mice although differences 
were less pronounced due to overall lower CCR4 positiv-
ity in both genotypes. Additionally, fewer CD4+ T cells 
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Fig. 1.  Phospholipase C epsilon 1 (PLCε1) limits murine colon adenocarcinoma (MC38) tumor growth and contributes to T cell subset distribution. 
(a) MC38 tumor volume calculated daily; n = 14 PLCε1 knock-out (KO) mice from three independent experiments with n ≥ 3 mice per experiment, 
n = 22 wild-type (WT) mice from four independent experiments with n ≥ 5 mice per experiment; points represent mean ± SEM. (b–e) Cells from 
spleens of normal (b) and tumor-bearing (c) mice along with the right inguinal lymph nodes (d) and tumors (e) from tumor-bearing mice were 
isolated and stained for CD3, CD4 and CD8 then analyzed by flow cytometry. Events were gated for live CD3+ events then CD4+ or CD8+; populations 
shown are total CD3+, CD3+ CD4+CD8−, CD3+CD4−CD8+; n = 4 WT and PLCε1 KO mice from two independent experiments with two mice per 
experiment per group; bars represent mean ± standard error of the mean (s.e.m.). *P ≤ 0·05, **P ≤ 0·01, ***P ≤ 0·001, ****P ≤ 0·0001, P > 0·05 not 
indicated.
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expressed CXCR4 in the spleens, LN and tumors of KO 
mice (Fig. 3b), suggesting that CCR4 and CXCR4 are 
critically contributing to T cell recruitment in this model. 
No consistent difference in the low level of CXCR3 
expression on CD4+ T cells was observed. Analysis of 
CXCR4, CCR4 and CXCR3 expression on CD8+ T cells 
did not uncover any differences (Supporting information, 
Fig. S4). This finding is consistent with the increased 
CD4+ T cell presence observed in KO mice (Fig. 1). No 
differences were observed in the expression of CCR7. 
Mechanistically, we also identified a defect in the PLCε1-
deficient CD4+ T cells migrating towards the CXCR4 
ligand SDF-1α (Fig. 3c). Importantly, no change in CXCR4 
surface expression was detected when PLCε1 was knocked 
down (Supporting information, Fig. S5), suggesting that 
the defect in migration is due to signaling differences 
downstream of CXCR4. These data, combined with the 
observation of fewer CCR4+ and CXCR4+ T cells in the 
study sites of PLCε1 KO mice, might suggest that these 
cells are unable to utilize these pathways to traffic to 
these sites. Overall, our data indicate a potential role for 
CCR4 and CXCR4 pathways in T cell localization within 
the tumor, and a role for PLCε1 in these signaling 
cascades.
Fig. 2. Activation of tumor infiltrating T cells requires phospholipase C epsilon 1 (PLCε1). Cells from spleens, lymph nodes and tumors from 
tumor-bearing mice were isolated and stained for CD3, CD4, CD8, CD44, PD-1 and CD62L then analyzed by flow cytometry. Events were gated for 
live CD3+ events then CD4+CD8− (a,b) or CD4−CD8+ (c, d); n = 4 of wild-type (WT) and PLCε1 knock-out (KO) mice from two independent 
experiments with two mice per experiment per group. LN = lymph nodes. Bars represent mean ± standard error of the mean (s.e.m.). *P ≤ 0·05, 
**P ≤ 0·01, ***P ≤ 0·001, ****P ≤ 0·0001, P > 0·05 not indicated.
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Discussion
Overall, this study is descriptive and preliminary. While 
it does not provide definitive proof of mechanism, it should 
be regarded as hypothesis-generating. We hypothesize that 
further development of this work will demonstrate a role 
for the enzyme PLCε1 in T cell distribution throughout 
multiple anatomical sites in tumor-bearing mice. Our find-
ing that CD4+ T cells are more abundant, less activated 
and express lower levels of CXCR4 and CCR4 in the 
spleens, LN and tumors of PLCε1 KO mice suggests to 
us that the overall trafficking of these cells relies upon 
PLCε1 function. While both CD4+ and CD8+ T cell fre-
quencies are altered in the absence of PLCε1, the observed 
chemokine receptor differences were preferentially within 
the CD4+ subset. Two possible explanations for this dis-
tinction are that either the disruption of CD4+ T cell 
migration and activation precedes and precludes CD8+ T 
cell activation and proliferation or that other PLCε1-
dependent chemokine receptors not quantified in this study 
may be preferentially expressed on CD8+ T cells. To address 
these hypotheses, more extensive and conclusive analysis 
of these pathways must be conducted.
We propose that PLCε1 is active downstream of CCR4, 
as we have shown previously for CXCR4 [13], and that 
these pathways may play critical roles in the proper 
localization of CD4+ T cells within the tumor microen-
vironment. We have shown previously that the impact 
of PLCε1 loss on inflammation was T cell intrinsic [13], 
although the indirect role for PLCε1 may be more wide-
spread. For example, one ligand for CCR4 is CCL2, which 
also binds the receptor CCR2, a chemokine receptor that 
is expressed highly on M2-like macrophages. In fact, 
CCL2–CCR2 engagement on macrophages has been shown 
to contribute to anti-inflammatory polarization of mac-
rophages with higher IL-10 production [19], poor antigen 
presentation and promotion of new blood vessel growth 
[20]. Each of these outcomes could lead to enhanced 
tumor growth. Lower levels of CCR4 on T cells within 
the same tumor microenvironment could lead to higher 
local levels of CCL2 available to interact with CCR2 on 
macrophages. Accordingly, we cannot rule out that PLCε1 
also plays a role in other types of immune cells.
This work is not free of limitations. Flow cytometry 
provides phenotype data and does not prove mechanism; 
this leaves open multiple mechanistic possibilities, as dis-
cussed and explored through in-vitro studies. While the 
mechanistic studies provided in this manuscript are not 
exhaustive, the cytotoxicity assay demonstrates that PLCε1 
expression in T cells does not contribute to cytotoxic 
function and the chemotaxis assay demonstrates that, in 
the absence of PLCε1, chemotaxis is significantly decreased 
in both human and murine T cells. Overall, the data 
included in this manuscript shows that MC38 tumors are 
larger in mice that do not express PLCε1, the T cell ratio 
is altered in multiple anatomical compartments in tumor-
bearing PLCε1 knock-out mice, T cell activation is 
decreased in multiple anatomical compartments in tumor-
bearing PLCε1 knock-out mice, PLCε1 knock-out T cells 
maintain cytotoxic function and PLCε1-depleted T cells 
do not respond to chemotactic stimuli to the same extent 
as wild-type T cells. From these data collectively, as well 
as the known literature on PLCε1, we conclude that PLCε1 
expression in T cells may contribute to an anti-tumor 
immune response.
Fig. 3. Infiltrating CD4+ T cells express different chemokine receptors in the absence of phospholipase C epsilon 1 (PLCε1). (a) Splenocytes from 
wild-type (WT) and PLCε1 knock-out (KO) mice were stimulated with Staphylococcus aureus enterotoxin E (SEE) for 72 h. Then CD8+ T cells were 
isolated and co-incubated with Raji cells and SEE for 4 h, after which lactate dehydrogenase (LDH) activity was quantified. Biological replicates were 
from n = 3 WT mice, n = 5 PLCε1 KO mice stimulated independently; points represent mean ± standard error of the mean (s.e.m.). (b) Cells from 
spleens, right inguinal lymph nodes and tumors were isolated and stained for CD3, CD4, CD8, CXCR4, CCR4 and CXCR3 then analyzed by flow 
cytometry. Events were gated for live CD3+ events then CD4+CD8−; n = 3–4 WT and PLCε1 KO mice from two independent experiments with two 
mice per experiment per group; points represent mean ± s.e.m; *P ≤ 0·05 based on comparison between WT and KO for individual chemokine 
receptors (indicated by dotted line), P > 0·05 not indicated. (c) Primary murine CD3+ T cells transfected with siRNA non-targeting (siScramble) or 
PLCε1 (siPLCε1) were added to the apical chamber of Transwell inserts with stromal cell-derived factor (SDF)-1α containing media in the basolateral 
chamber. After 3 h cells in the basolateral chamber were quantified; n = 3 independent experiments, each performed in duplicate. Bars indicate 
mean ± s.e.m. *P ≤ 0·05.
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It would be of interest to assess the combined impact 
of PLCε1 activation with checkpoint inhibition within a 
tumor model, given that enhanced tumor infiltration is 
critical to T cell-mediated tumor clearance. A recent study 
published in Immunity [21] took the first steps in linking 
the chemokine network with anti-PD-1 treatment. Their 
work concludes that CXCR3 expression on CD8+ T cells 
is critical for proper localization within the tumor and 
anti-PD-1 efficacy. With further work to uncover the 
mechanism underlying the role for PLCε1 in these 
chemokine pathways, we suggest that local activation of 
PLCε1 within T cells may be a viable therapeutic strategy 
in the treatment of solid tumors.
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Supporting Information
Additional supporting information may be found in the on-
line version of this article at the publisher’s web site:
Fig. S1. The top 33% of PLCε1 expression (high) in rec-
tum adenocarcinoma samples from the TCGA correlated 
with increased survival compared to the lowest 33% of 
PLCε1 expression (low). Log rank P-value = 0.0772 (http://
www.oncol nc.org/kapla n/?lower =33&upper =33&cance 
r=READ&gene\_xml:id=51196 &raw=plce1 &speci es=m-
RNA) (a) Tumors were excised and weighed from mice that 
survived to day 25 post tumor inoculation (b) n = 4 PLCε1 
KO mice, n = 12 WT mice from 3 independent experiments; 
bars represent min - max. ****P ≤ 0.0001.
Fig. S2. CD3+ CD4+ CD8- cells were analyzed for expres-
sion of CD25 and FoxP3, with double positive (CD25+ 
FoxP3+) cells being regarded as regulatory T cells (Treg). 
Bars represent the mean % of CD4+ cells that were 
Treg ± SEM.
Fig. S3. Cells from spleens, lymph nodes, and tumors 
from tumor-bearing mice were isolated and stained for 
CD3, CD4, CD8, CD44, PD-1, and CD62L then analyzed 
by flow cytometry. Events were gated for live CD3+ events 
then CD4+ CD8- (a,b) or CD4- CD8+ (c,d). Plots repre-
sentative of n  =  4 WT and PLCε1 KO mice from 2 in-
dependent experiments with 2 mice per experiment per 
group.
Fig. S4. Cells from spleens, right inguinal lymph nodes, and 
tumors from tumor-bearing mice were isolated and stained 
for CD3, CD4, CD8, CXCR4, CCR4, and CXCR3 then ana-
lyzed by flow cytometry. CD3+ CD4- CD8+ cells are included 
in this analysis. n = 4 WT and PLCε1 KO mice from 2 inde-
pendent experiments with 2 mice per experiment per group; 
points represent mean ± SEM.
Fig. S5. (a) Jurkat T cells expressing shRNA non-targeting 
(shScramble) or PLCε1 (shPLCε1) were added to the api-
cal chamber of transwell inserts with SDF-1α containing 
media in the basolateral chamber. After 3 hours cells in the 
basolateral chamber were quantified. n  =  3 independent 
experiments, each performed in duplicate. Bars indicate 
mean ± SEM; *P ≤ 0.05. (b) Jurkat T cells expressing shScram-
ble or shPLCε1 were stained with APC-conjugated isotype or 
CXCR4 antibody and analyzed by flow cytometry to assess 
CXCR4 expression.
